Company / Capital Expenditures
NewAmsterdam Pharma Co N.V. Capital Expenditures History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$246.0K
FY2025
5-year range
$24.0K / $672.0K
FY2021-FY2025
Trend
-63.4%
vs FY2024
Sector context
#157 of 195
Health Care
What the data says
NewAmsterdam Pharma Co N.V.'s capital expenditures of $246,000 is lower than 81% of companies in the Health Care sector (FY2025). Capital Expenditures has fluctuated over the past 5 years, ranging from $24,000 in FY2023 to $672,000 in FY2024.
Based on SEC 10-K filings.
$246,000 in FY2025 with a 3-year CAGR of +3.6%.
Improved from $24,000 to $246,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +3.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
-99.8% below sector average
Key checks
Key Insights
- 3-year CAGR of +3.6%, indicating consistent growth.
- In FY2025, capital expenditures decreased 63.4% year-over-year.
- Ranks #157 out of 195 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $246.0K | -63.4% |
| FY2024 | $672.0K | +2700.0% |
| FY2023 | $24.0K | -89.1% |
| FY2022 | $221.0K | +820.8% |
| FY2021 | $24.0K | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026